Cellspace HA™ 3D bioactive HA scaffold for next-generation cell-based bioproduction
CellSpace HA™ is a proprietary 3D crosslinked hyaluronic acid scaffold engineered to replace conventional 2D cell culture delivering dramatically higher yields, lower costs, and continuous biologics production across multiple modalities. What it is & how it works: A drop-in solid bioactive matrix compatible with standard flasks (T25→T225), Erlenmeyers, Petri dishes and stirred-tank bioreactors up to 5,000L same protocol at every scale, zero CapEx, 100% animal-free. Cells anchor within the 3D HA matrix, eliminating loss at medium change and enabling continuous secretion over months. Proof to date: ≥12× mAb yield vs. 2D standard (hybridoma model independently validated); +54% EV yield/mL with homogeneous 140nm size (MSC-derived); −80% cost/unit; 5+ months matrix stability. Compatible with mAb, EV, recombinant protein and LVV manufacturing. Next steps: Seeking industry partners for pilot engagements, co-development, sponsored research and supply agreements. Currently scaling HA microcarriers for bioreactor format (H2 2026). AI digital twin (OctoSim™) in development for process prediction and optimization.
About OctoCells
Octocells is a French biotechnology company based in Rouen that develops advanced three-dimensional (3D) cell culture solutions for bioproduction and research. Their core offering, the CellSpace HA platform, utilizes a patented, animal-free hyaluronic acid-based bioscaffold. This technology is designed to address limitations in traditional 2D culture and animal-derived matrices by providing a highly scalable, standardized, and reproducible environment for cell growth. The system supports a variety of applications, including oncology, cell therapies, vaccine production, regenerative medicine, and cultivated proteins. By combining expertise in biomaterials with digital technologies—such as the potential use of digital twins for bioreactor simulation—the company aims to optimize production processes, reduce costs, and improve overall bioproduction efficiency.
The company's solutions are intended to assist researchers and industrial partners in scaling production while maintaining ethical standards and consistent biological results. The CellSpace HA system is compatible with standard lab formats and allows for adjustable stiffness, facilitating high-density cell growth and extended culture durations. Through these innovations, Octocells addresses critical industry barriers related to reproducibility and the ethical impact of production. The company was founded in 2022 by Zied Souguir and Grégory Maubon, and it maintains strategic partnerships and membership in biotechnology incubators to accelerate the transition of its technologies from research settings to industrial and clinical applications.
delivered to your inbox.